Top 5 Articles

Latest information from the EIPG Website
  1. Comments received on ‘Draft Guideline on manufacture of the finished dosage form’

    The European Medicines Agency have published: Scientific guideline: Overview of comments received on ‘Draft Guideline on manufacture of the finished dosage form’ (EMA/CHMP/QWP/245074) – Revision 1.
  2. Devices used with regenerative medicine advanced therapies

    The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled “Evaluation of Devices Used with Regenerative Medicine Advanced Therapies; Draft Guidance for Industry.”
  3. Activities of the European Ombudsman in 2016

    European Parliament resolution of 16 November 2017 on the annual report on the activities of the European Ombudsman in 2016 (2017/2126(INI)) (P8_TA -PROV(2017)0449).
  4. Assessing user fees Under the Biosimilar User Fee Amendments of 2017

    The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Assessing User Fees Under the Biosimilar User Fee Amendments of 2017.”
  5. Relocation of the European Medicines Agency

    Answer given by President Juncker on 15.11.2017 on behalf of the Commission to question for written answer to the Commission by Christel Schaldemose (Date : 21-09-2017 Reference : P-005871/2017)